CureDuchenne - Together we Can CureDuchenne
April 2013

Drisapersen Update Webinar with GSK on May 6, 2013

The purpose of the “Drisapersen Update” webinar with GSK is to update the Duchenne community about Phase II clinical trial results for GSK’s drisapersen drug for the treatment of Duchenne muscular dystrophy. GSK investigator John Kraus will present and answer submitted questions. CureDuchenne, in collaboration with MDA and PPMD, is pleased to co-sponsor this webinar.

To register for the webinar, click here.